CommentaryGuanylate Cyclase C Agonists: Emerging Gastrointestinal Therapies and Actions
Section snippets
Chemistry of GC-C Receptor Agonists
UG, guanylin (GN), lymphoguanylin, and bacterial enterotoxin ST of E coli (which is responsible for travelers’ diarrhea) are structurally related peptides that activate the GC-C receptor, which is selectively expressed in brush border membranes of enterocytes from the duodenum to the rectum.4 Complementary DNAs encoding the precursors of GN, UG, and lymphoguanylin have been isolated, revealing that the active peptides are found at C-terminal ends of 100–116 amino acid proteins that possess
Intestinal and Colonic Chloride Secretion
Linaclotide is the first GC-C agonist approved for moderate to severe IBS-C and chronic idiopathic constipation.11, 12, 13 Pharmacodynamic studies showed that the GC-C agonist accelerated gastrointestinal transit,14 probably through increased fluid secretion. Preclinical studies (discussed elsewhere in this article) showed that it reduced visceral hypersensitivity. Linaclotide acts locally in the gastrointestinal tract with minimal systemic exposure, resulting in low oral bioavailability and,
Future Directions
GC-C agonists have demonstrated clinical impact as laxatives and visceral analgesics. Future research is likely to elaborate on anti-inflammatory and antineoplastic effects of this pathway, its mediators, and its modulators. These increasingly understood actions may, in fact, have an even greater impact in clinical practice than the actions on secretion and visceral sensation. The advances, from understanding a pathogenic toxin to a new drug class with many potential therapeutic benefits,
References (35)
- et al.
Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C
Am J Hum Genet
(2012) Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology
Regul Pept
(1999)- et al.
Guanylin, an endogenous ligand for C-type guanylate cyclase, is produced by goblet cells in the rat intestine
Gastroenterology
(1995) - et al.
Uroguanylin is expressed by enterochromaffin cells in the rat gastrointestinal tract
Gastroenterology
(1997) - et al.
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome
Gastroenterology
(2007) - et al.
IFN-gamma induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction
Gastroenterology
(2006) - et al.
Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation
Pain
(2013) - et al.
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity
Gastroenterology
(2007) - et al.
The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling
Gastroenterology
(2010) - et al.
Intestinal cell proliferation and senescence is regulated by receptor guanylyl cyclase C and p21
J Biol Chem
(2014)
Familial diarrhea syndrome caused by an activating GUCY2C mutation
N Engl J Med
RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study
Am J Physiol
Regulation of intestinal Cl- and HCO3-secretion by uroguanylin
Am J Physiol
Guanylin: A peptide regulator of epithelial transport
FASEB J
Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity
Proc Natl Adad Sci U S A
Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses
Dig Dis Sci
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation
Am J Gastroenterol
Cited by (34)
Just how prevalent are peptide therapeutic products? A critical review
2020, International Journal of PharmaceuticsCitation Excerpt :Linaclotide and plecanatide are both agonists of guanylate cyclase-C (GC-C), and they have local effects on the luminal surface of the intestinal epithelium. The activation of GC-C ultimately leads to accelerated GI transit and increased release of intestinal fluid (Camilleri, 2015). Elobixibat is minimally absorbed in circulation when taken orally; however, it acts locally in the lumen of the GI tract by binding to and partially inhibiting ileal bile acid transporter (IBAT) in the ileal mucosa (Acosta and Camilleri, 2014).
Theoretical structural characterization of lymphoguanylin: A potential candidate for the development of drugs to treat gastrointestinal disorders
2017, Journal of Theoretical BiologyCitation Excerpt :Up to now, three drugs derived from GPs or guanylin-like peptides have been approved or are in the approval process at the US Food and Drug administration (FDA): Linaclotide (Ironwood Pharmaceuticals Inc, Boston, MA, USA and Forest Laboratories Inc, New York, NY, USA) is derived from E. coli STa, while Plecanatide and Dolcanatide (Synergy Pharmaceuticals Inc, New York, NY, USA) are both analogs of UGN used to treat gastrointestinal disorders, despite UGN renal function. These drugs have been described as excellent options for the treatment of gastrointestinal disorders such as irritable bowel syndrome with constipation (Busby et al., 2010; Camilleri, 2015; Shailubhai et al., 2013), chronic idiopathic constipation (Camilleri, 2015; Shailubhai et al., 2015) and ulcerative colitis (Shailubhai et al., 2015, 2013). For this reason, analogs of GPs could be considered as promising drugs for controlling gastrointestinal disorders.
The Role of Ion Channels in Functional Gastrointestinal Disorders (FGID): Evidence of Channelopathies and Potential Avenues for Future Research and Therapeutic Targets
2023, International Journal of Molecular SciencesBig peptide drugs in a small molecule world
2023, Frontiers in Chemistry
Conflicts of interest The author declares no conflicts.